Cornelia de Lange Syndrome 5 (CdLS5, HDAC8-related) — Comprehensive Disease Report

MONDO:0010471 · OMIM #300882 · Orphanet ORPHA:199 (CdLS group) · Gene: HDAC8 (Xq13.1)

Evidence source key: [H] human clinical/genetic; [M] model organism; [V] in vitro/biochemical; [C] computational/epigenomic. PMIDs cited throughout.

1. Disease Information

Overview. Cornelia de Lange syndrome type 5 (CdLS5) is the X-linked form of Cornelia de Lange syndrome caused by loss-of-function variants in HDAC8, the gene encoding histone deacetylase 8, the enzyme that deacetylates the cohesin subunit SMC3. CdLS is a multisystem congenital malformation and neurodevelopmental disorder characterized by distinctive facial features, growth restriction (pre- and postnatal), intellectual disability, upper-limb anomalies, hirsutism/hypertrichosis, and involvement of the cardiac, gastrointestinal, genitourinary and other systems [H, 29995837; 30614194]. CdLS is a "cohesinopathy" and, more broadly, a disorder of transcriptional regulation (DTR) [H, 37377026]. HDAC8-related CdLS is frequently non-classic/atypical, and in many patients the clinical diagnosis was not suspected before genomic testing [H, 24403048].

Key identifiers. - MONDO: MONDO:0010471 (Cornelia de Lange syndrome 5) - OMIM phenotype: #300882; OMIM gene HDAC8: 300269 - Orphanet: ORPHA:199 (Cornelia de Lange syndrome, umbrella) - Gene: HDAC8, HGNC:13315, NCBI Gene 55869, Ensembl ENSG00000147099, UniProt Q9BY41; cytoband Xq13.1 - ICD-10: Q87.1 (congenital malformation syndromes predominantly associated with short stature); ICD-11: LD2F.1Y/typically coded under multiple-anomaly syndromes; MeSH: D003635 (De Lange Syndrome)

Synonyms/alternative names. CdLS5; HDAC8-related Cornelia de Lange syndrome; X-linked Cornelia de Lange syndrome; Cornelia de Lange syndrome due to HDAC8 deficiency; historically overlapping terms: Brachmann–de Lange syndrome. "Wilson–Turner-like" X-linked ID has been noted for some HDAC8 variants in the differential.

Data provenance. This report is compiled from aggregated disease-level resources (OMIM, Orphanet, HPO, consensus statements) and published patient cohorts (e.g., 38-patient HDAC8 cohort [PMID 24403048]; 716-proband CdLS cohort [PMID 37377026]); not from individual EHR data.

2. Etiology

Primary cause — genetic. Hemizygous (males) or heterozygous (females) loss-of-function variants in HDAC8 [H, 24403048; 22885700]. HDAC8 is the vertebrate SMC3 deacetylase; CdLS-causing variants abolish enzymatic activity ("all cause a loss of enzymatic function") [H/V, 24403048].

Genetic risk factors. - Causal variants: predominantly missense and largely de novo; also nonsense, frameshift, splice, and deletions [H, 24403048]. - Modifier of expressivity in females: pattern of X-chromosome inactivation (XCI). Skewed XCI silencing the mutant allele attenuates phenotype; random/unfavorable XCI increases severity [H, 24403048; 26671848]. - Broader locus heterogeneity: other CdLS genes (NIPBL, SMC1A, SMC3, RAD21, BRD4, ANKRD11) cause overlapping phenotypes; genetic background may modify.

Environmental risk factors. None established. CdLS is a monogenic Mendelian disorder; no confirmed toxic, infectious, dietary, or occupational cause. Male sex is a risk factor for greater severity in HDAC8-CdLS (hemizygosity, no XCI buffering) [H, 24403048]. Family history relevant when a carrier mother is mosaic.

Protective factors. The principal "protective" mechanism is favorable (skewed) X-inactivation in heterozygous females, which can render carriers mildly affected or clinically unaffected [H, 26671848]. No dietary/lifestyle protective factors are known. gnomAD constraint (HDAC8 highly intolerant to LoF) argues against benign LoF variation.

Gene–environment interactions. Not established; disease is essentially fully genetically determined. The main "gene–gene/epigenetic" interaction is XCI × mutant allele.

3. Phenotypes

HDAC8-CdLS overlaps classic CdLS but is often milder and has discriminating features. Frequencies below are drawn from CdLS-spectrum and HDAC8 cohorts [PMID 24403048; 30614194; 29995837]; HDAC8-specific frequencies are smaller-N.

Craniofacial (near-universal; congenital). - Synophrys / arched eyebrows — HP:0000664 / HP:0000574 (characteristic across CdLS) [PMID 30614194] - Short nose with anteverted nares, depressed bridge — HP:0003196 / HP:0000463 [PMID 30614194] - Long philtrum, thin upper vermilion — HP:0000343 / HP:0000219 [PMID 30614194] - Micrognathia — HP:0000347; low-set/posteriorly rotated ears - HDAC8-discriminating: delayed anterior fontanelle closure (HP:0001476), ocular hypertelorism (HP:0000316), hooding of eyelids, broader nose, dental anomalies (HP:0000164) [H, 24403048]. "often displays delayed anterior fontanelle closure, ocular hypertelorism, hooding of the eyelids, a broader nose and dental anomalies, which may be useful discriminating features" [PMID 24403048].

Growth (congenital/childhood, chronic). Prenatal and postnatal growth restriction — HP:0001511 / HP:0001510; microcephaly (often postnatal) — HP:0000252 [PMID 30614194]. Severity generally milder in HDAC8 than NIPBL.

Neurodevelopment (childhood, lifelong). Intellectual disability — HP:0001249; global developmental delay — HP:0001263; speech delay — HP:0000750. HDAC8 cases trend milder cognitively than NIPBL but ID is typical.

Neurobehavioral/psychiatric (childhood → adult; persistent). - Autism spectrum features — HP:0000717 (significantly elevated vs comparison syndromes) [H, 23937369]; ASD criteria may increase over time [PMID 30941551] - Anxiety — HP:0000739 (common, persistent; intolerance of uncertainty a driver) [PMID 36199025; 40878447] - Self-injurious behavior — HP:0100716; stereotypies — HP:0000733 - Catatonia-like attenuated behavior in ~30.3% of CdLS [PMID 29536582]

Limb (congenital). Upper-limb reduction defects (oligodactyly, absent forearm) — HP:0009821/HP:0002984 are characteristic of severe NIPBL CdLS but typically ABSENT or mild in HDAC8-CdLS [PMID 24403048; 30158690]. Small hands/feet, 5th-finger clinodactyly (HP:0004209) may occur.

Other systems. Hirsutism/hypertrichosis — HP:0001007; congenital heart defects — HP:0001627 (e.g., septal defects, pulmonary stenosis); gastro-esophageal reflux and GI dysmotility — HP:0002020; cryptorchidism/genital anomalies — HP:0000028; hearing loss — HP:0000365; ptosis — HP:0000508; myopia/ophthalmologic issues; seizures — HP:0001250 (subset). Male hemizygotes more severely affected [PMID 24403048].

Quality-of-life impact. Substantial: lifelong intellectual disability, communication limits, anxiety, self-injury, GI symptoms, and feeding difficulty impair adaptive functioning and caregiver burden [PMID 36199025; 29536582]. Disease-specific/formal QoL instrument data (EQ-5D/SF-36) are limited for CdLS5 specifically — not available at HDAC8 subtype resolution.

4. Genetic / Molecular Information

Causal gene. HDAC8 (HGNC:13315; OMIM 300269), Xq13.1, encoding a class I zinc-dependent histone/lysine deacetylase; physiological substrate for the CdLS mechanism is cohesin subunit SMC3 (acetyl-K105/K106) [H/V, 22885700].

Pathogenic variants. - Types: predominantly missense (clustered around catalytic residues/active site), plus nonsense, frameshift, splice-site, and intragenic/whole-gene deletions [H, 24403048]. Recurrent examples reported include p.His180Arg, p.Gly304 region, p.Thr311Met, and catalytic-domain substitutions (variant-level detail curated in ClinVar/HGMD). - Classification (ACMG/AMP): pathogenic/likely pathogenic for LoF and functionally validated missense; some VUS resolved by enzymatic assay or DNA-methylation episignature. - Allele frequency: essentially absent from population databases (gnomAD) — consistent with a highly constrained, disease-causing gene. - Origin: germline, mostly de novo; maternal mosaicism documented (unaffected mother mosaic → two affected sibs) [H, 26671848]. HDAC8 somatic mutations occur in cancers but are unrelated to CdLS. - Functional consequence: loss of function / loss of enzymatic (deacetylase) activity [H/V, 24403048].

Modifier genes / factors. X-inactivation pattern is the dominant modifier in females [PMID 26671848]. NIPBL expression level correlates with severity across CdLS broadly [PMID 27125329]. No specific trans-modifier gene proven for HDAC8.

Epigenetic information. CdLS displays a reproducible genome-wide DNA-methylation "episignature" usable diagnostically; it can confirm diagnosis in mutation-negative patients and reclassify VUS, though sensitivity is heterogeneous across CdLS cases [C/H, 38751117; 37872275]. Mechanistically, HDAC8 loss alters SMC3 acetylation and cohesin-dependent chromatin architecture/transcription [V, 22885700].

Chromosomal abnormalities. CdLS5 is a single-gene disorder; large Xq13 deletions encompassing HDAC8 can cause it and are detectable by CMA. Otherwise no characteristic karyotypic change.

5. Environmental Information

Environmental factors: none established. Lifestyle factors: none causal (monogenic disorder). Infectious agents: not applicable. (Environmental contribution is essentially nil; disease is genetically determined.)

6. Mechanism / Pathophysiology

Causal chain (initiating lesion → clinical manifestation)

1. A loss-of-function HDAC8 variant results in loss of HDAC8 lysine-deacetylase activity [H/V, 24403048].
2. Loss of HDAC8 activity leads to failure to deacetylate SMC3 (acetyl-K105/K106) during mitotic exit → increased/retained SMC3 acetylation [V, 22885700].
3. Retained-acetyl SMC3 results in inefficient dissolution of the "used" cohesin complex released from chromatin (prophase and anaphase) and its improper recycling/reloading [V, 22885700].
4. This leads to decreased occupancy at cohesin binding sites genome-wide → altered chromatin architecture and gene transcription (a pattern shared with NIPBL-mutant CdLS) [V, 22885700].
5. Dysregulated developmental transcription results in abnormal patterning/differentiation of multiple lineages, notably cranial neural crest — (branch, demonstrated in mouse): HDAC8 loss de-represses homeobox factors Otx2 and Lhx1 in cranial neural crest, leading to skull/craniofacial malformation [M, 19605684].
6. Multilineage transcriptional dysregulation during embryogenesis results in the CdLS phenotype: craniofacial dysmorphism, growth restriction, CNS/neurodevelopmental and behavioral abnormalities, limb, cardiac, and GI anomalies [H, 29995837].
7. (Female branch) Skewed X-inactivation silencing the mutant HDAC8 allele attenuates the phenotype; hemizygous males lack this buffering and are more severely affected [H, 24403048; 26671848].

Note on inference: Steps 1–4 are biochemically demonstrated in human cells; step 5 (Otx2/Lhx1) is demonstrated in mouse neural crest and inferred to underlie human craniofacial features; step 6 is the clinical–molecular correlation.

Detail by category

• Molecular pathways: cohesin cycle / sister-chromatid cohesion establishment–dissolution; cohesin-mediated chromatin looping and enhancer–promoter regulation (Reactome "Cohesin Loading onto Chromatin," "Establishment of Sister Chromatid Cohesion"). Downstream developmental TF networks (Otx2, Lhx1). Not a classic signaling cascade (Wnt/MAPK) primarily, though cohesin regulates many such loci.
• Cellular processes: GO:0016575 histone deacetylation; GO:0007062 sister chromatid cohesion; GO:0006325 chromatin organization; GO:0006351 transcription; cell-fate specification/patterning; cranial neural crest migration/differentiation. Increased apoptosis of neural crest in Hdac8-null skull [M, 19605684].
• Protein dysfunction: loss of catalytic deacetylase activity (Zn2+-dependent hydrolase, InterPro/Pfam PF00850 Hist_deacetyl; PDB structures of HDAC8 available). Missense variants disrupt catalysis/substrate binding → LoF [V, 24403048].
• Biochemical abnormality: enzyme deficiency — SMC3-lysine deacetylase (HDAC8) [V, 22885700].
• Epigenetic changes: aberrant SMC3 acetylation; altered histone deacetylation of neural-crest TF loci; reproducible blood DNA-methylation episignature [PMID 22885700; 38751117].
• Immune/metabolic involvement: not central; no primary immunodeficiency/metabolic defect characteristic of CdLS5.
• Transcriptomics: CdLS cell lines (NIPBL or HDAC8 mutant) share a consistent altered transcription profile with reduced cohesin site occupancy [V, 22885700].
• Cell types (CL) / anatomy (UBERON): CL:0000333 cranial neural crest cell; UBERON:0003129 skull; UBERON:0001890 forebrain.

7. Anatomical Structures Affected

• Organ/system level (primary): craniofacial skeleton/skull (UBERON:0003129), central nervous system/brain (UBERON:0000955), musculoskeletal/limbs (upper limb UBERON:0002102). Secondary/associated: heart (UBERON:0000948), gastrointestinal tract incl. esophagus (UBERON:0001043)/gut, genitourinary tract (UBERON:0000079), ears/auditory system (UBERON:0001690), eyes (UBERON:0000970), skin/hair (hypertrichosis).
• Body systems: nervous, craniofacial/skeletal, cardiovascular, digestive, genitourinary, integumentary, sensory (auditory/visual), endocrine (growth).
• Tissue/cell level: connective/skeletal (cranial bones), nervous tissue; key developmental population = cranial neural crest cells (CL:0000333) [M, 19605684].
• Subcellular (GO cellular component): GO:0005634 nucleus; GO:0000785 chromatin; GO:0008278 cohesin complex; GO:0005737 cytoplasm (HDAC8 also cytoplasmic).
• Localization/lateralization: malformations are generally bilateral/symmetric (craniofacial midline and paired structures); limb involvement, when present in the broader spectrum, can be asymmetric.

8. Temporal Development

• Onset: congenital — malformations arise in embryogenesis; growth restriction detectable prenatally; dysmorphism recognizable at birth [H, 29995837]. Onset pattern: chronic/static malformation with developmental unfolding.
• Progression: Non-progressive at the malformation level; lifelong/chronic course. Neurobehavioral features (autism traits, anxiety, catatonia-like attenuation) can emerge or intensify across childhood into adulthood [H, 30941551; 29536582]. Adaptive ability tends to be stable with some receptive-language gains [PMID 30941551].
• Patterns: No remission (structural/genetic). Critical period: early embryonic neural-crest/organogenesis window sets the malformation; postnatally, early developmental/behavioral intervention is the actionable window.

9. Inheritance and Population

• Epidemiology: CdLS (all genes) estimated incidence/prevalence ~1/10,000–1/30,000 [H, 32800026]. HDAC8 accounts for a minority (~4–5%) of CdLS; CdLS5 is correspondingly rarer. Precise CdLS5 prevalence: not separately established.
• Inheritance: X-linked (Xq13.1). De novo in most; can be inherited from a carrier/mosaic mother [PMID 24403048; 26671848].
• Penetrance/expressivity: Highly variable expressivity; in females penetrance/severity is modulated by X-inactivation (can be near-nonpenetrant with fully skewed favorable XCI) [PMID 26671848]. Males: essentially penetrant, more severe.
• Genetic anticipation: not applicable (not a repeat-expansion disorder).
• Germline/somatic mosaicism: documented maternal mosaicism with sibling recurrence [PMID 26671848]; relevant to recurrence-risk counseling.
• Founder effects/consanguinity/carrier frequency: no founder effect; consanguinity not relevant (X-linked, mostly de novo); carrier frequency negligible in general population (gnomAD LoF depleted).
• Population demographics: No ethnic predilection; CdLS occurs across global populations with consistent core features [H, 30614194]. Sex ratio: both sexes affected; males more severely affected, females often milder/atypical [PMID 24403048]. Age distribution: present from birth through adulthood.

10. Diagnostics

• Clinical criteria: 2018 first international consensus provides diagnostic criteria for classic and non-classic CdLS and a cardinal/suggestive feature scoring approach; recommends molecular confirmation [H, 29995837]. Facial-analysis technology aids recognition across populations (sensitivity ≥95%, specificity ≥91%) [PMID 30614194].
• Genetic testing (recommended, definitive):
• Multigene NGS panel / WES / WGS covering the seven CdLS/DTR genes incl. HDAC8 — first-line; HDAC8 sequencing is "indispensable" in CdLS workup [H, 26671848]. WGS adds detection of structural/deep-intronic variants.
• Single-gene HDAC8 sequencing when HDAC8 phenotype suspected.
• Chromosomal microarray (CMA) to detect Xq13 deletions/CNVs.
• Deep/mosaicism-aware sequencing of multiple tissues (buccal, fibroblasts) because somatic/parental mosaicism is common in CdLS [PMID 26671848].
• X-inactivation assay in females to interpret expressivity [PMID 24403048].
• Omics-based diagnostics: DNA-methylation episignature as an orthogonal classifier to confirm mutation-negative CdLS and reclassify VUS [C, 38751117; caution on sensitivity per 37872275]. Functional SMC3-deacetylation/enzyme assays can validate missense VUS [V, 24403048].
• Supportive clinical tests: echocardiography (CHD), hearing and ophthalmologic evaluation, GI/reflux workup, renal ultrasound, growth monitoring, developmental/behavioral assessment (per consensus surveillance) [PMID 29995837].
• Differential diagnosis: classic NIPBL-CdLS and other cohesinopathy genes (SMC1A, SMC3, RAD21); CdLS-like DTRs (ANKRD11/KBG, EP300, AFF4/CHOPS, TAF1, BRD4); Warsaw breakage syndrome (DDX11), Roberts syndrome (ESCO2), fetal alcohol spectrum, Coffin–Siris, Rubinstein–Taybi [H, 31721174; 36703504].
• Screening: No population newborn screening (not applicable). Cascade/carrier and prenatal testing offered once a familial variant is known; prenatal ultrasound may show IUGR, limb/heart anomalies.

11. Outcome / Prognosis

• Survival/life expectancy: Many individuals survive into adulthood, particularly milder (incl. many HDAC8) cases; life expectancy is influenced by complications (severe CHD, GI/aspiration, infections). Formal CdLS5-specific survival statistics: not established. Hemizygous males (more severe) have poorer prognosis than mildly affected skewed-XCI females [PMID 24403048].
• Morbidity/function: Lifelong intellectual disability and behavioral morbidity (anxiety, ASD, self-injury, catatonia-like features) dominate disability burden [PMID 36199025; 29536582]. Growth failure, feeding/GI problems, hearing/vision deficits contribute.
• Complications: GERD and GI dysmotility, aspiration, recurrent infections, congenital heart disease, seizures, behavioral crises/self-injury.
• Recovery potential: Malformations are static; developmental and behavioral outcomes are improvable with early intervention/therapy; no cure.
• Prognostic factors: genotype/gene (HDAC8 milder than NIPBL), sex and X-inactivation pattern, severity of CHD/GI disease, degree of ID. No validated molecular prognostic biomarker beyond gene/variant and XCI [PMID 24403048; 27125329].

12. Treatment

No disease-modifying/curative therapy exists; management is multidisciplinary and supportive, per the 2018 consensus [H, 29995837].

• Supportive/medical (NCIT: C15277 Supportive Care):
• GI: anti-reflux medical therapy (proton-pump inhibitors — NCIT C29708; H2 blockers), nutritional support, fundoplication/gastrostomy for severe GERD/feeding failure.
• Cardiac: surgical/medical management of congenital heart defects.
• ENT/audiology: hearing aids, myringotomy tubes for otitis; ophthalmology for ptosis/refractive error.
• Growth/endocrine: nutritional optimization; growth monitoring.
• Neurology: anti-seizure medication if epilepsy.
• Neurobehavioral/psychiatric (NCIT C15313 Psychosocial/Behavioral therapy; C265 Pharmacotherapy): behavioral therapy for self-injury/ASD; SSRIs (e.g., sertraline — NCIT C47727) for anxiety/OCD-like symptoms; treat pain/occult GI sources of behavioral change; address intolerance of uncertainty in anxiety interventions [PMID 40878447; 36199025].
• Surgical/interventional (NCIT C15329 Surgery): cardiac repair, fundoplication/gastrostomy, orchidopexy for cryptorchidism, cleft/orthodontic and other reconstructive procedures as indicated.
• Rehabilitative: physical, occupational, and speech/language therapy; special education; early developmental intervention.
• Advanced/experimental therapeutics: None approved. No gene, cell, RNA, or targeted therapy in clinical use for CdLS5. HDAC-modulation strategies are conceptual/preclinical only; no CdLS-specific trials identified. Pharmacogenomics: no CdLS5-specific PGx guidance.
• Treatment strategy: individualized, guided by the consensus care/surveillance pathway; genotype-informed counseling but not yet genotype-targeted drug therapy [PMID 29995837].

13. Prevention

• Primary prevention: Not possible (mostly de novo genetic disorder). Prevention centers on reproductive counseling for families with a known variant.
• Secondary prevention: Early molecular diagnosis → structured surveillance (cardiac, GI, hearing, vision, growth, behavioral) to detect and treat complications early [PMID 29995837].
• Tertiary prevention: Aggressive management of GERD/aspiration, CHD, and behavioral/self-injury to prevent morbidity.
• Genetic screening/counseling: genetic counseling (X-linked risks, de novo vs mosaic recurrence), prenatal testing / PGT when a familial variant is known; test/counsel potentially mosaic mothers given documented sibling recurrence [PMID 26671848]. NSGC/ACMG counseling frameworks apply.
• Immunization/public-health/environmental measures: not applicable beyond routine pediatric care.

14. Other Species / Natural Disease

• Taxonomy/orthologs: HDAC8 is conserved across vertebrates. Mouse Hdac8 (NCBI Gene 70315; NCBI Taxon 10090); also conserved in rat, zebrafish. Cohesin/SMC3 machinery conserved from yeast (Hos1 is the yeast SMC3 deacetylase analog) to humans [PMID 22885700].
• Natural disease in other species: No well-characterized naturally occurring HDAC8-CdLS in companion/wild animals reported in OMIA; not applicable/none documented. Veterinary relevance: none established.
• Comparative biology: The cohesin acetylation cycle and neural-crest role of Hdac8 are evolutionarily conserved, underpinning cross-species disease modeling [PMID 22885700; 19605684].
• Transmission/zoonosis: not applicable (genetic disorder).

15. Model Organisms

• Mouse (Mus musculus, NCBI Taxon 10090) — primary model [M, 19605684]:
• Global Hdac8 knockout: perinatal lethality due to skull instability — models the craniofacial malformation.
• Conditional (cranial neural crest–specific, e.g., Wnt1-Cre) knockout: phenocopies the skull defect, localizing pathogenesis to cranial neural crest.
• Mechanistic readout: HDAC8 represses homeobox TFs Otx2 and Lhx1; loss de-represses them → aberrant skull patterning; increased neural-crest apoptosis.
• Recapitulation: strong for craniofacial/skull patterning; limitations: global KO perinatal lethality limits study of postnatal neurobehavioral phenotypes; does not capture X-inactivation mosaicism of human females.
• Zebrafish (Danio rerio) / cohesinopathy models: cohesin (nipbl, esco2, rad21) models reproduce craniofacial and developmental gene-expression phenotypes, supporting the transcriptional-dysregulation mechanism shared with HDAC8 [M, 29084713].
• In vitro / cellular models: patient-derived lymphoblastoid/fibroblast lines showing increased SMC3 acetylation, reduced cohesin occupancy, and altered transcription [V, 22885700]; recombinant HDAC8 enzymatic assays to test variant activity [V, 24403048]. iPSC/organoid HDAC8-CdLS models: an emerging but not yet standard resource.
• Model databases: MGI (mouse Hdac8), IMPC, ZFIN (zebrafish), Alliance of Genome Resources.

Summary Answer

Cornelia de Lange syndrome 5 is the X-linked (Xq13.1) form of CdLS caused by loss-of-function variants in HDAC8, the deacetylase for the cohesin subunit SMC3. Impaired SMC3 deacetylation disrupts the cohesin acetylation/recycling cycle and cohesin-dependent transcriptional regulation during development (a "cohesinopathy"/disorder of transcriptional regulation), producing a multisystem malformation and neurodevelopmental syndrome that overlaps classic CdLS but is often milder/atypical, with discriminating features (delayed fontanelle closure, ocular hypertelorism, dental anomalies); hemizygous males are more severely affected, while heterozygous females are variably affected depending on X-inactivation. Management is multidisciplinary and supportive with no disease-modifying therapy; diagnosis rests on consensus clinical criteria plus molecular testing (with episignature/functional assays as adjuncts).

Key Limitations

• Many phenotype frequencies and prognosis/QoL data are CdLS-spectrum-level, not HDAC8-specific (small N for CdLS5).
• No CdLS5-specific survival, incidence, or clinical-trial data; therapeutics remain supportive.
• Variant-level ClinVar/gnomAD counts were not directly queried in this literature-based synthesis and should be verified in those databases for KB population.

Primary References (PMIDs)

22885700 (Deardorff 2012, Nature, HDAC8=SMC3 deacetylase/mechanism); 24403048 (Kaiser 2014, 38-patient HDAC8 cohort, X-linked, discriminating features); 26671848 (Parenti 2016, HDAC8 spectrum, skewed XCI, maternal mosaicism); 19605684 (Haberland 2009, Hdac8 mouse skull/neural crest, Otx2/Lhx1); 29995837 (Kline 2018, first international consensus); 37377026 (Kaur 2023, 716 probands, DTR framing); 30614194 (Dowsett 2019, diverse populations); 30158690 (Yuan 2019, mild end of spectrum); 27125329 (Kaur 2016, NIPBL levels/severity); 23937369, 36199025, 29536582, 30941551, 40878447 (CdLS neurobehavioral phenotype); 38751117, 37872275 (episignature diagnostics); 31721174 (chromatinopathies review); 29084713 (zebrafish cohesinopathy model).